2016
Impact of TCFA on Unanticipated Ischemic Events in Medically Treated Diabetes Mellitus Insights From the PROSPECT Study
Kedhi E, Kennedy MW, Maehara A, Lansky AJ, McAndrew TC, Marso SP, De Bruyne B, Serruys PW, Stone GW. Impact of TCFA on Unanticipated Ischemic Events in Medically Treated Diabetes Mellitus Insights From the PROSPECT Study. JACC Cardiovascular Imaging 2016, 10: 451-458. PMID: 27372016, DOI: 10.1016/j.jcmg.2015.12.023.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedChi-Square DistributionCoronary AngiographyCoronary Artery DiseaseCoronary VesselsDiabetes MellitusDisease ProgressionFemaleFibrosisHumansMaleMiddle AgedPercutaneous Coronary InterventionPlaque, AtheroscleroticPredictive Value of TestsPropensity ScoreRisk FactorsRupture, SpontaneousTime FactorsTreatment OutcomeUltrasonography, InterventionalConceptsMajor adverse cardiac eventsAcute coronary syndromeThin-cap fibroatheromaNonculprit lesionsDiabetes mellitusACS patientsDM patientsSubsequent major adverse cardiac eventsPresence of DMPROSPECT studyAdverse cardiac eventsPropensity-matched groupsRadiofrequency intravascular ultrasoundHigh rateCoronary syndromeCardiac eventsPlaque compositionIntravascular ultrasoundPatientsPropensity scoreBalanced groupsIschemicMellitusFibroatheromaPrognosis
2014
Long-Term Outcome of PCI Versus CABG in Insulin and Non–Insulin-Treated Diabetic Patients Results From the FREEDOM Trial
Dangas GD, Farkouh ME, Sleeper LA, Yang M, Schoos MM, Macaya C, Abizaid A, Buller CE, Devlin G, Rodriguez AE, Lansky AJ, Siami FS, Domanski M, Fuster V, Investigators F. Long-Term Outcome of PCI Versus CABG in Insulin and Non–Insulin-Treated Diabetic Patients Results From the FREEDOM Trial. Journal Of The American College Of Cardiology 2014, 64: 1189-1197. PMID: 25236509, DOI: 10.1016/j.jacc.2014.06.1182.Peer-Reviewed Original ResearchConceptsCoronary artery bypass graft surgeryInsulin-treated diabetes mellitusPercutaneous coronary interventionDrug-eluting stentsDeath/stroke/myocardial infarctionStroke/myocardial infarctionNon-ITDM patientsFREEDOM trialMyocardial infarctionClinical outcomesUnderwent coronary artery bypass graft surgeryMajor adverse cardiovascular eventsMultivessel coronary artery diseaseArtery bypass graft surgeryLong-term clinical outcomesEvent ratesCoronary lesion complexityDiabetes mellitus statusIndex revascularization procedureAdverse cardiovascular eventsBypass graft surgeryPrimary composite endpointCoronary artery diseaseBetter clinical outcomesDiabetic patients results
2012
Plaque Composition and Clinical Outcomes in Acute Coronary Syndrome Patients With Metabolic Syndrome or Diabetes
Marso SP, Mercado N, Maehara A, Weisz G, Mintz GS, McPherson J, Schiele F, Dudek D, Fahy M, Xu K, Lansky A, Templin B, Zhang Z, de Bruyne B, Serruys PW, Stone GW. Plaque Composition and Clinical Outcomes in Acute Coronary Syndrome Patients With Metabolic Syndrome or Diabetes. JACC Cardiovascular Imaging 2012, 5: s42-s52. PMID: 22421230, DOI: 10.1016/j.jcmg.2012.01.008.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAngina, UnstableAngioplasty, Balloon, CoronaryChi-Square DistributionCoronary AngiographyCoronary Artery DiseaseCoronary StenosisDiabetes MellitusEuropeFemaleHeart ArrestHumansKaplan-Meier EstimateMaleMetabolic SyndromeMiddle AgedMultivariate AnalysisMyocardial InfarctionNecrosisPlaque, AtheroscleroticPredictive Value of TestsProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTomography, X-Ray ComputedTreatment OutcomeUltrasonography, InterventionalUnited StatesVascular CalcificationConceptsMajor adverse cardiac eventsGreater necrotic coreUntreated nonculprit lesionsAcute coronary syndromeMet SynNonculprit lesionsPercutaneous coronary interventionSYN patientsNecrotic coreMACE rateMetabolic syndromePlaque burdenFuture major adverse cardiac eventsSubsequent major adverse cardiac eventsAcute coronary syndrome patientsSuccessful percutaneous coronary interventionGreater plaque burdenAdverse cardiac eventsCoronary syndrome patientsHigh-risk groupQuantitative coronary angiographySmaller lumen areaACS patientsCoronary syndromeACS population
2011
Usefulness of Minimum Stent Cross Sectional Area as a Predictor of Angiographic Restenosis After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (from the HORIZONS-AMI Trial IVUS Substudy)
Choi SY, Maehara A, Cristea E, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA, Dressler O, Lansky AJ, Parise H, Mehran R, Mintz GS, Stone GW. Usefulness of Minimum Stent Cross Sectional Area as a Predictor of Angiographic Restenosis After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (from the HORIZONS-AMI Trial IVUS Substudy). The American Journal Of Cardiology 2011, 109: 455-460. PMID: 22118823, DOI: 10.1016/j.amjcard.2011.10.005.Peer-Reviewed Original ResearchConceptsMinimum stent areaST-segment elevation myocardial infarctionBare-metal stent useElevation myocardial infarctionAngiographic restenosisMyocardial infarctionStent areaIndependent predictorsStent usePrimary percutaneous coronary interventionStable coronary artery diseaseLumen areaMinimum stent cross-sectional areaDifferent antithrombotic regimensIntravascular ultrasound substudyPrimary percutaneous interventionStent cross-sectional areaPercutaneous coronary interventionCoronary artery diseaseAcute myocardial infarctionAverage lumen areaMinimum lumen areaIVUS minimum lumen areaAntithrombotic regimensAttenuated plaqueDevelopment of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients
Elashoff MR, Wingrove JA, Beineke P, Daniels SE, Tingley WG, Rosenberg S, Voros S, Kraus WE, Ginsburg GS, Schwartz RS, Ellis SG, Tahirkheli N, Waksman R, McPherson J, Lansky AJ, Topol EJ. Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients. BMC Medical Genomics 2011, 4: 26. PMID: 21443790, PMCID: PMC3072303, DOI: 10.1186/1755-8794-4-26.Peer-Reviewed Original ResearchConceptsObstructive coronary artery diseaseCoronary artery diseaseNon-diabetic patientsDiabetic statusArtery diseaseRT-PCR analysisNon-invasive blood testStudy of patientsPeripheral blood cellsClassifier genesCell type-specific markersPREDICT cohortGene expressionClinical factorsInvasive angiographyBlood testsControl cohortRegistry casesCohort analysisPREDICT studyResultsMicroarray analysisDiagnostic utilityPopulation predictorsRT-PCR dataCAD association
2010
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients.
Rosenberg S, Elashoff MR, Beineke P, Daniels SE, Wingrove JA, Tingley WG, Sager PT, Sehnert AJ, Yau M, Kraus WE, Newby LK, Schwartz RS, Voros S, Ellis SG, Tahirkheli N, Waksman R, McPherson J, Lansky A, Winn ME, Schork NJ, Topol EJ. Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Annals Of Internal Medicine 2010, 153: 425-34. PMID: 20921541, PMCID: PMC3786733, DOI: 10.7326/0003-4819-153-7-201010050-00005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAlgorithmsArea Under CurveChest PainCoronary AngiographyCoronary Artery DiseaseDiabetes MellitusFemaleGene ExpressionHumansMaleMiddle AgedProspective StudiesReverse Transcriptase Polymerase Chain ReactionRisk AssessmentROC CurveSensitivity and SpecificitySex FactorsYoung AdultConceptsObstructive coronary artery diseaseCoronary artery diseaseCoronary angiographyNondiabetic patientsQuantitative coronary angiographyArtery diseasePresence of CADClinical modelMore major coronary arteriesPeripheral blood gene expressionBlood-based gene expression testDiamond-Forrester methodMulticenter prospective trialMajor coronary arteriesChronic inflammatory disordersIndependent validation cohortReceiver-operating characteristic analysisBlood gene expressionReal-time polymerase chain reactionWhole blood testCardiac protein markersGene expression testNoninvasive imaging methodProspective trialRisk patients
2008
A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study
Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB, Schofer J, Buchbinder M, Wijns W, Group C. A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study. Journal Of The American College Of Cardiology 2008, 51: 1543-1552. PMID: 18420096, DOI: 10.1016/j.jacc.2008.01.020.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicChromium AlloysClopidogrelCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDiabetes MellitusFemaleHumansMaleMiddle AgedPaclitaxelPlatelet Aggregation InhibitorsPolymersRiskThromboembolismTiclopidineTime FactorsConceptsPercutaneous coronary interventionTarget vessel revascularizationDrug-eluting stentsMajor adverse cardiac eventsMultivessel percutaneous coronary interventionTaxus drug-eluting stentsMyocardial infarctionAdjudicated deathAdverse cardiac eventsPrimary end pointSegment late lossSingle target lesionPre-specified subgroupsStent thrombosis ratesTreatment of SingleVessel revascularizationCardiac eventsCoronary interventionII studyThrombosis rateAngiographic analysisEpicardial vesselsTarget lesionsLate lossPatients